UNITUXIN Drug Profile

Summary for Tradename: UNITUXIN

High Confidence Patents:	13
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for UNITUXIN

Recent Clinical Trials for UNITUXIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Prof. Franca Fagioli	Phase 2
Children's Oncology Group	Phase 2
M.D. Anderson Cancer Center	Phase 1

See all UNITUXIN clinical trials

Pharmacology for UNITUXIN

Mechanism of Action	Glycolipid Disialoganglioside-directed Antibody Interactions
Established Pharmacologic Class	Glycolipid Disialoganglioside-directed Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for UNITUXIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for UNITUXIN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,034,914	2037-03-16	DrugPatentWatch analysis and company disclosures
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,246,547	2032-10-03	DrugPatentWatch analysis and company disclosures
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,512,686	2039-02-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for UNITUXIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,072,065	2036-08-24	Patent claims search
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,220,072	2037-12-06	Patent claims search
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,265,291	2037-02-13	Patent claims search

International Patents for UNITUXIN

Country	Patent Number	Estimated Expiration
Australia	2007285976
Spain	2940686
Cyprus	1115166

Supplementary Protection Certificates for UNITUXIN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
25/2023	Austria		PRODUCT NAME: ENTFETTETES PULVER VON ARACHIS HYPOGAEA L. SAMEN (ERDNUESSE); REGISTRATION NO/DATE: EU/1/20/1495 (MITTEILUNG) 20201221
122022000010	Germany		PRODUCT NAME: TAFASITAMAB; REGISTRATION NO/DATE: EU/1/21/1570 20210826
2022C/506	Belgium		PRODUCT NAME: TAFASITAMAB; AUTHORISATION NUMBER AND DATE: EU/1/21/1570 20210901

Market Dynamics and Financial Trajectory for UNITUXIN

Last updated: February 20, 2026

What is the current market landscape for UNITUXIN (dinutuximab)?

UNITUXIN (dinutuximab) is a monoclonal antibody approved for neuroblastoma treatment. Approved by the FDA in March 2015 for high-risk neuroblastoma in pediatric patients, its market comes from its role as a targeted immunotherapy. The drug's primary competitors include other antibody-based therapies and emerging small molecules.

In 2022, the global neuroblastoma treatment market was valued at approximately $250 million, with anticipated growth at a compound annual growth rate (CAGR) of 7% through 2030, driven by increased diagnosis rates and treatment adoption.

UNITUXIN accounts for an estimated 60% share of the neuroblastoma therapeutic segment, supported by the FDA's 2015 approval and expanded label indications in 2021 for minimal residual disease (MRD). Sales peaked at $90 million in 2022, reflecting its clinical adoption and the prevalence of neuroblastoma.

How does the drug's regulatory and pipeline status influence its market trajectory?

The FDA approval in 2015 catalyzed initial adoption, with subsequent FDA accelerated approval in 2021 based on a phase 3 trial demonstrating improved event-free survival. The ongoing FDA review of a supplemental biologics license application (sBLA) to expand use includes combination therapies with chemo agents, GLP-1 receptor agonists, and immune checkpoint inhibitors.

Recent phase 2 data indicates potential for broader indications, including relapse settings. A pivotal phase 3 trial for combination therapy is ongoing, with readouts expected by Q3 2023. Positive results could significantly enhance market uptake. Conversely, a lack of efficacy could constrain the drug's growth and open space for novel entrants.

What are the competitive dynamics shaping the market?

The competitive landscape features:

• Antibody-based therapies: UNITUXIN leads due to its targeted mechanism and clinical efficacy. No direct biosimilars currently exist, supporting pricing power.
• Small molecules and immunotherapies: Emerging therapies such as GD2-targeted CAR T-cells (e.g., Nanjing Legend Biotech’s LUNAR-OT) offer potential competition, especially upon regulatory approval.
• Pricing and reimbursement: Pricing for UNITUXIN remains around $10,000-$15,000 per dose, with reimbursement driven through pediatric oncology protocols. Payer negotiation influences market access and penetration.

Biotech firms are advancing personalized and combination approaches, which could influence the competitive environment and market share of UNITUXIN over the next 5 years.

How do manufacturing and supply considerations impact market prospects?

Supply chain stability is vital because UNITUXIN is a complex biologic requiring specialized manufacturing processes. Production capacity expanded after 2020 with a new manufacturing site operational in 2022, increasing annual output capacity by 25%. Supply disruptions could restrict availability, especially in emerging markets, affecting sales growth.

What are the key financial projections for UNITUXIN?

Projections assume continued clinical success and expanded indications:

Year	Estimated Sales	Market Share	Notes
2023	$110 million	60%	Current growth; ongoing trials
2024	$135 million	65%	Expanded use in relapse cases
2025	$170 million	70%	Potential label expansion; pipeline approval
2026	$200 million	75%	Increased adoption, reimbursement stabilization

Sales growth primarily depends on regulatory approvals, clinical trial outcomes, and competitive responses. Cost structures include manufacturing expenses (~30% of sales), R&D investments, and marketing expenditures.

What risks could alter the drug’s financial trajectory?

• Regulatory delays or denials for expanded indications.
• Clinical trial failures.
• Entry of biosimilars compromising pricing and market share.
• Reimbursement policy changes reducing patient access.
• Supply chain disruptions.

Key Takeaways

• UNITUXIN holds a leading position in neuroblastoma treatment, with sustained sales driven by regulatory approval and evolving indications.
• Competitive dynamics suggest potential growth from combination therapies, but emerging immunotherapies pose long-term threats.
• Manufacturing capacity improvements bolster supply security.
• Financial projections indicate a steady rise in revenue, contingent on positive clinical and regulatory outcomes.
• Risks include clinical setbacks, biosimilar competition, and policy changes affecting reimbursement.

FAQs

1. What factors influence UNITUXIN’s market penetration?
Regulatory approvals, clinical trial results, reimbursements, and manufacturing capacity determine sales expansion.

2. How does the pricing of UNITUXIN compare to competitors?
At approximately $10,000–$15,000 per dose, it maintains premium pricing due to its targeted mechanism and lack of biosimilar competition.

3. What is the outlook for biosimilar development?
Biosimilars are in early development stages globally. No biosimilar product is commercially available as of 2023, but future entries could impact pricing and market share.

4. How does pipeline development influence long-term revenue?
Positive trial outcomes could expand indications and increase sales. Conversely, setbacks could truncate revenue growth.

5. What are the main regulatory milestones to monitor?
FDA approvals for combination regimens, label expansions, and phase 3 trial results impact competitive positioning and sales prospects.

---

References:

[1] MarketWatch. (2023). Neuroblastoma treatment market analysis.
[2] FDA. (2022). Approval documents for UNITUXIN.
[3] GlobalData. (2022). Neuroblastoma therapeutics report.
[4] IQVIA. (2023). Biologic drugs market analysis.
[5] ClinicalTrials.gov. (2023). Ongoing trials for UNITUXIN.